[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
Submission ::
Ethics::
Registration::
Contact us::
Site Facilities::
::
Impact Factor
Impact Factor 2022: 1.9
5-Year Impact Factor: 2.2
Cite Score 2022: 3.9
SJR 2022: 0.447
SNIP 2022: 0.538

 
..
Publication Fee
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 12, Issue 3 (Int J Mol Cell Med 2023) ::
Int J Mol Cell Med 2023, 12(3): 229-241 Back to browse issues page
Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of BCL-2
Kaveh Tari1 , Ahmad Nasimian2 , Julhash U Kazi2 , Saied Abroun 3
1- Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
2- Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
3- Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. , abroun@modares.ac.ir
Abstract:   (497 Views)
Venetoclax, a specific inhibitor of the BCL2 protein, is administered for the treatment of acute lymphoblastic leukemia. However, despite being utilized in conjunction with chemotherapy, the drug exhibits instances of resistance. The exact mechanisms responsible for this resistance remain relatively obscure. Within the context of this investigation, the study aimed to explore the involvement of anti- and pro-apoptotic proteins as one of the potential mechanisms underlying this resistance phenomenon. Blast cells were extracted from patients diagnosed with B&T acute lymphoid leukemia. Subsequently, these cells were subjected to a cultivation process. Following the cultivation, treatment with the Venetoclax drug was administered to both groups of B&T cells. Additionally, one group from each cell type was designated as a control. The relative expression levels of genes BCL-2, MCL-1, and BIM were assessed in comparison to the control group. Annexin V–fluorescein isothiocyanate and propidium iodide staining was done to check cell apoptosis. The results showed a significant increase in the expression of BIM gene and a significant decrease in BCL-2 gene compared to the control group, but the change in the expression of MCL-1 gene was not significant. Also, an increase in apoptosis was observed in the treatment groups compared to the control. Although it was shown that changes in the expression of pro- and anti-apoptotic genes can lead to an increase in cell apoptosis and a decrease in the number of blast cells, more studies are needed to investigate the simultaneous effect of Venetoclax drug with other drugs and also in the form of a clinical trial.
Keywords: Venetoclax, acute lymphoblastic leukemia, apoptosis, BCL-2
Full-Text [PDF 720 kb]   (121 Downloads)    
Type of Study: Original Article | Subject: Hematology
Received: 2023/12/3 | Accepted: 2024/01/16 | Published: 2024/03/16
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tari K, Nasimian A, Kazi J U, Abroun S. Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of BCL-2. Int J Mol Cell Med 2023; 12 (3) :229-241
URL: http://ijmcmed.org/article-1-2253-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 12, Issue 3 (Int J Mol Cell Med 2023) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.05 seconds with 38 queries by YEKTAWEB 4652